The year was looking bright for Exact Sciences. The company planned to build on its 2019 acquisition of Genomic Health to create a multifaceted diagnostic testing company in 2020, but COVID-19-related disruptions altered the plan for the year.
Exact Sciences' 2020 had several notable events in 2020. Exact:
February: Completed 477,000 Cologuard tests in the fourth quarter of 2019 and 1.68 million tests in 2019.
March: Donates money to Fight Colorectal Cancer to launch the Catalyst State-by-State Advocacy Program. The program funds efforts to advance legislation that promotes CRC screening.
March 3: Acquires Paradigm and Viomics. The companies expand Exact's lab testing and research and development capabilities.
March 19: Withdraws first-quarter and annual guidance for 2020 because of COVID-19. Allows employees to work remotely while maintaining laboratory testing capabilities to handle Cologuard tests.
May: Reports revenues of $347.8 million for the first quarter and a net loss of $105.7 million. Doesn't report screening figures.
July: Reports revenues of $268.9 million for the quarter and a net loss of $86.1 million. Doesn't report screening figures.
October: Introduces its Oncotype MAP Pan-Cancer Tissue test. The diagnostic test screens for advanced, metastatic, refractory or recurrent cancers. The test provides information to physicians to understand a patient's tumor profile.
Oct. 7: Extends and amends its Cologuard promotion agreement with Pfizer. The agreement has been largely successful and has increased Cologuard adoption rates.
Oct. 27: Acquires Thrive for its CancerSeek platform. Claims it has become a leader in blood-based, multi-cancer screening.
Oct. 27: Revenues recover from COVID-19-related disruption. Reports $408.4 million in revenues and a net loss of $219.9 million. Doesn't report testing figures.
December: Donates $10 million Stand Up To Cancer. The funds will be used to establish a team of researchers and launch a public awareness campaign around increasing screenings.
More articles on surgery centers:
Ohio health system acquires surgery center for $21M
2 Texas health systems suspend surgeries, others don't
Stryker's ASC-focused business: 3 things to know